secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001171843-25-005260
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Q2 net loss $19.9M; CTX-8371 shows deep responses; tovecimig OS readout moves to Q1 2026
--------------------------------------------------------------------------------

- Net loss Q2 2025 $19.9M ($0.14/share) vs $13.1M ($0.10/share) in Q2 2024; R&D expenses rose 47% to $16.4M.
- Tovecimig Ph2/3 BTC trial met primary endpoint (ORR 17.1% vs 5.3%, p=0.031); OS analysis delayed to Q1 2026 due to fewer deaths.
- CTX-8371 Ph1: confirmed PR in NSCLC with 100% target lesion reduction and TNBC with >90% reduction; expansion cohorts planned Q4 2025.
- CTX-10726 (PD-1 x VEGF-A) showed superior PD-1 inhibition and tumor control vs ivonescimab preclinically; IND filing on track for Q4 2025.
- Cash and marketable securities $101M as of June 30, 2025; expected cash runway into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/0001171843-25-005260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/f8k_080925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer